Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1

Conditions

Stomach Neoplasms 7Rectal Neoplasms 5Nasopharyngeal Carcinoma 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms by Site 1

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Recurrence × spartalizumab × Clear all
NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Chinese PLA General Hospital

Phase 1/2 Recruiting
250 enrolled

Neoplasms, Recurrence

NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Chinese PLA General Hospital

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis, Recurrence

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
218 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡